Brødkrumme Forside Spero Therapeutics Spero Therapeutics Spero has a pipeline of novel treatments for multi-drug resistant (MDR) bacterial infections. Two programs are in clinical phase I Related news about Spero Therapeutics Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Spero Therapeutics Announces First Quarter 2023 Operating Results and Provides a Business Update GSK and Spero Therapeutics Announce Exclusive License Agreement for Late-Stage Antibiotic Asset, Tebipenem HBr Spero Therapeutics Provides Tebipenem HBr Program Update Following Type A Meeting with the U.S. Food and Drug Administration Spero Therapeutics Receives Complete Response Letter from U.S. Food and Drug Administration for Tebipenem HBr New Drug Application Spero Therapeutics website Lundbeckfonden BioCapital Investeringsår 2015 IPO in 2017 – SPRO (Nasdaq) Lokation Boston, Massachusetts, USA
